PMID- 12378599
OWN - NLM
STAT- MEDLINE
DCOM- 20021217
LR  - 20191210
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 96
IP  - 5
DP  - 2002 Oct 25
TI  - A fluorescence in situ hybridization-based assay for improved detection of lung 
      cancer cells in bronchial washing specimens.
PG  - 306-15
AB  - BACKGROUND: Interphase fluorescence in situ hybridization (FISH) is a powerful 
      tool for detecting chromosome and locus-specific changes in tumor cells. We 
      developed a FISH-based assay to detect genetic changes in bronchial washing 
      specimens of lung carcinoma patients. METHODS: The assay uses a mixture of 
      fluorescently labeled probes to the centromeric region of chromosome 1 and to the 
      5p15, 8q24 (site of the c-myc gene), and 7p12 (site of the EGFR gene) loci to 
      assess cells in bronchial washing specimens for chromosomal abnormalities 
      indicative of lung carcinoma. The FISH assay was performed on 74 specimens that 
      had been assessed previously for evidence of malignancy by routine cytology with 
      Pap staining. RESULTS: Forty-eight patients had histologically confirmed lung 
      carcinoma and 26 patients had a clinical diagnosis that was negative for lung 
      carcinoma. FISH analysis was performed without knowledge of the patient's 
      clinical information. The finding of six or more epithelial cells with gains of 
      two or more chromosome regions was considered a positive FISH result (i.e., 
      evidence of malignancy). The sensitivity of FISH for the detection of lung 
      carcinoma was 82% in this set of specimens compared with a 54% sensitivity by 
      design for cytology (FISH vs. cytology, P = 0.007). FISH detected 15 of 18 
      specimens that were falsely negative by cytology. The specificities of FISH and 
      cytology were 82% and 100%, respectively, and were not significantly different (P 
      = 0.993). CONCLUSIONS: The data indicate a potential utility of the FISH assay as 
      an adjunct to bronchial washing cytology in routine clinical practice.
CI  - Copyright 2002 American Cancer Society.
FAU - Sokolova, Irina A
AU  - Sokolova IA
AD  - Vysis, Inc., Downers Grove, Illinois 60515, USA. isokolova@vysis.com
FAU - Bubendorf, Lukas
AU  - Bubendorf L
FAU - O'Hare, Anna
AU  - O'Hare A
FAU - Legator, Mona S
AU  - Legator MS
FAU - Jacobson, Kris K B
AU  - Jacobson KK
FAU - Grilli B S, Bruno
AU  - Grilli B S B
FAU - Dalquen, Peter
AU  - Dalquen P
FAU - Halling, Kevin C
AU  - Halling KC
FAU - Tamm, Michael
AU  - Tamm M
FAU - Seelig, Steven A
AU  - Seelig SA
FAU - Morrison, Larry E
AU  - Morrison LE
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adenocarcinoma/*diagnosis
MH  - Bronchoalveolar Lavage Fluid/*cytology
MH  - Feasibility Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis
MH  - *ROC Curve
MH  - Sensitivity and Specificity
EDAT- 2002/10/16 04:00
MHDA- 2002/12/18 04:00
CRDT- 2002/10/16 04:00
PHST- 2002/10/16 04:00 [pubmed]
PHST- 2002/12/18 04:00 [medline]
PHST- 2002/10/16 04:00 [entrez]
AID - 10.1002/cncr.10720 [doi]
PST - ppublish
SO  - Cancer. 2002 Oct 25;96(5):306-15. doi: 10.1002/cncr.10720.